Aura Biosciences, Inc.

8-K · aura-20260611.htm iXBRL

0001501796 2026-06-11 2026-06-11

  
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
  
 FORM 8-K
  
 CURRENT REPORT
 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 Date of Report (Date of earliest event reported): June 11, 2026

  
  
 Aura Biosciences, Inc.
 (Exact name of Registrant as Specified in Its Charter)
  
  

 Delaware

 001-40971

 32-0271970

 (State or Other Jurisdiction
of Incorporation)

 (Commission File Number)

 (IRS Employer
Identification No.)

  

  

  

  

  

 80 Guest Street

  

 Boston, Massachusetts

  

 02135

 (Address of Principal Executive Offices)

  

 (Zip Code)

  

 Registrant’s Telephone Number, Including Area Code: 617 500-8864

  

 Not Applicable

 (Former Name or Former Address, if Changed Since Last Report)
  
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  

 ☐

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  

  

 ☐

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  

  

 ☐

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

  

 ☐

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  
 Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

 Trading
Symbol(s)

  

Name of each exchange on which registered

 Common Stock, $0.00001 par value per share

  

 AURA

  

 The Nasdaq Global Market

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 Emerging growth company ☒
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  

 Item 5.07 Submission of Matters to a Vote of Security Holders.
  
 On June 11, 2026, Aura Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The proposals set forth below were submitted to the stockholders at the Annual Meeting, with each such proposal described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 20, 2026.
 The number of shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”), entitled to vote at the Annual Meeting was 64,199,778. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 52,784,744. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each proposal voted upon at the Annual Meeting are set forth below.
 Proposal 1 - Election of Directors
 The Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class II directors to serve until the 2029 Annual Meeting of Stockholders of the Company and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal.

 Director Nominee

 Votes For

 Votes Withheld

 Broker
Non-Votes

 David Johnson

 34,542,193

  

  

  

 6,628,297

  

  

  

 11,614,254

 Teresa Marie Bitetti

 40,526,332

  

  

  

 644,158

  

  

  

 11,614,254

  
 Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm
 The Company’s stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.

 Votes For

  

 Votes Against

  

 Abstentions

 52,752,601

  

 17,348

  

 14,795

  
 There were zero broker non-votes regarding this proposal.
  

 SIGNATURES
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  

  

  

  

 Aura Biosciences, Inc.

  

  

  

  

 Date:

 June 11, 2026

 By:

 /s/ Natalie Holles

  

  

  

 Natalie Holles
 Chief Executive Officer and President
 (Principal Executive Officer)